-
公开(公告)号：US20230322867A1
公开(公告)日：2023-10-12
申请号：US18006689
申请日：2021-07-22
Applicant: AMGEN INC.
Inventor： Fernando GARCES , Zhulun WANG , Timothy RILEY
IPC: C07K14/165 , C12N15/85 , C07K16/10
CPC classification number: C07K14/165 , C07K16/10 , C12N15/85 , A61K2039/505
Abstract: The present invention relates to severe acute respiratory syndrome coronavirus 2 (“SARS-CoV2”) immunogens useful for the generation of therapeutic antibodies and vaccine development. Such therapeutic antibodies include human antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV2 S protein, and that function to neutralize SARS-CoV2. The present invention also relates to methods of generating antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV2 S protein.
-
公开(公告)号：US20240002545A1
公开(公告)日：2024-01-04
申请号：US18252442
申请日：2021-11-09
Applicant: AMGEN INC.
Inventor： Timothy RILEY , Fernando GARCES , Zhulun WANG , Bram Estes , Darren L. Bates
IPC: C07K16/46
CPC classification number: C07K16/468 , C07K2317/55 , C07K2317/64 , C07K2317/31
Abstract: The ability to generate a single antibody-based construct that can recognize multiple targets simultaneously, is paramount to advance many therapeutics candidates to clinic. Often, this implies extensive protein design with vary degrees of success. In the case of multispecific antibodies, the driving of the HC/LC pairing in the Fab region represents one of the most difficult challenges yet in the field of multispecific engineering. Described here is the discovery of a new single chain Fab module that utilizes a novel linker between VL-CL and VH-CH1 domains which will further enable the production of multispecifics.
-
公开(公告)号：US20220363770A1
公开(公告)日：2022-11-17
申请号：US17621189
申请日：2020-06-26
Applicant: AMGEN INC.
Inventor： Irwin CHEN , Su CHONG , Fernando GARCES , Mark Leo MICHAELS , Christopher MOHR , Kenneth William WALKER , Zhulun WANG , Neeraj Jagdish AGRAWAL , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Derek E. PIPER , Cen XU
Abstract: The present invention relates to antagonist antibodies of the human calcitonin gene-related peptide (CGRP) receptor as well as bispecific antigen binding proteins derived from the anti-CGRP antibodies that bind to and inhibit both the human CGRP receptor and another target, such as the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) receptor. Pharmaceutical compositions comprising the anti-CGRP receptor antibodies and bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the anti-CGRP receptor antibodies and bispecific antigen binding proteins to ameliorate, treat, or prevent conditions associated with the CGRP and PAC1 receptors, such as chronic pain, migraine, and cluster headache, are also described.
-
4.发明公开公开(公告)号：US20240182600A1
公开(公告)日：2024-06-06
申请号：US18556248
申请日：2022-04-19
Applicant: AMGEN INC.
Inventor： Danyang GONG , Bram ESTES , Zhulun WANG , Fernando GARCES
IPC: C07K16/46
CPC classification number: C07K16/468 , C07K2317/31 , C07K2317/526
Abstract: The clinical potential of multispecific antibodies like bispecific and trispecific antibodies shows great promise for targeting complex diseases. However, the generation of those molecules presents great challenges particularly in regard to achieving acceptable expression levels free from mis-paired polypeptides. The presently claimed invention is directed to multispecific antigen binding proteins which improve upon existing charge pair technologies by redistributing the engineered charges within the CH3 regions of a heteromultimer.
-
公开(公告)号：US20220235148A1
公开(公告)日：2022-07-28
申请号：US17615555
申请日：2020-05-29
Applicant: Amgen Inc.
Inventor： Fernando GARCES , Zhulun WANG
Abstract: The clinical potential of multispecific antibodies like bispecific and trispecific antibodies shows great promise for targeting complex diseases. However, the generation of those molecules presents great challenges as in many cases it is desired to specifically drive the specific pairing of multiple polypeptide chains that are present in solutions. In the case of the heavy chains, there are two main regions that form a dimer interface. One of them is the CH3 region, which has been widely exploited by inserting either charge-pair mutations (CPMs) to steer the dimer interface or inserting large bulky residues into cavities (Knob in Hole) to physically favor and disfavor the dimer formation. However, each of these strategies may not be applied to every molecule and therefore there is the need for more tools. Here, we describe the engineering of the Hinge region with a small number of mutations that are capable to alone successfully drive the heavy chain dimerization.
-
Patent Agency Ranking
公开(公告)号：US20210347905A1
公开(公告)日：2021-11-11
申请号：US17127629
申请日：2020-12-18
Applicant: Amgen Inc.
Inventor： Xin YU , Jackson EGEN , Fernando GARCES , Shunsuke TAKENAKA , AeRyon KIM , Deepali SAWANT
Abstract: The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.
-
7.发明公开公开(公告)号：US20240150481A1
公开(公告)日：2024-05-09
申请号：US18417708
申请日：2024-01-19
Applicant: Amgen Inc.
Inventor： Xin YU , Jackson EGEN , Fernando GARCES , Shunsuke TAKENAKA , AeRyon KIM , Deepali SAWANT
CPC classification number: C07K16/2878 , A61P35/04 , C07K16/30 , A61K2039/505
Abstract: The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.
-
公开(公告)号：US20230374162A1
公开(公告)日：2023-11-23
申请号：US18248345
申请日：2021-10-05
Applicant: AMGEN INC.
Inventor： Danyang GONG , Fernando GARCES , Zhulun WANG
CPC classification number: C07K16/468 , C12N15/63 , C07K2317/31 , C07K2317/565 , C07K2317/55 , C07K2317/622
Abstract: The ability to generate a single antibody-based construct that can recognize multiple targets simultaneously, is paramount to advance many therapeutics candidates to clinic. Often, this implies extensive protein design with vary degrees of success. In the case of multispecific antibody constructs, there are multiple modalities from which to choose and often multiple antigen binders as well. Described here is the discovery of new methods to optimally pair antigen binders with the proper format, including the selection of common light chains.
-
公开(公告)号：US20230322955A1
公开(公告)日：2023-10-12
申请号：US18042267
申请日：2021-08-19
Applicant: AMGEN INC.
Inventor： Fernando GARCES , Zhulun WANG
IPC: C07K16/46
CPC classification number: C07K16/468 , C07K2317/31 , C07K2317/55 , C07K2317/51 , C07K2317/54
Abstract: The ability to generate a single antibody-based construct that can recognize multiple targets simultaneously, is paramount to advance many therapeutics candidates to clinic. Often, this implies extensive protein design with vary degrees of success. In the case of multispecific antibodies, the driving of the HC/LC pairing in the Fab region represents one of the most difficult challenges yet in the field of multispecific engineering. Described here is the discovery of a new placement for a non-canonical disulfide bond and as such the generation of an asymmetric cysteine interface between two Fabs present in the same molecule which will further enable the production of multispecifics.
-
公开(公告)号：US20230047631A1
公开(公告)日：2023-02-16
申请号：US17778361
申请日：2020-11-18
Applicant: AMGEN INC.
Inventor： Fernando GARCES , Zhulun WANG
IPC: C07K16/46
Abstract: The present invention relates to novel multispecific antigen binding proteins that are capable of binding to multiple targets. Pharmaceutical compositions comprising the multispecific antigen binding proteins as well as methods for producing them are also disclosed.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.024 seconds)
